Phthalimide conjugation as a strategy for in vivo target protein degradation

Cited by (1,004)

Items 501–600 of 1,004

1. Exploiting ubiquitin ligase cereblon as a target for small-molecule compounds in medicine and chemical biology
   Takumi Ito, Yuki Yamaguchi, Hiroshi Handa · 2021 · Cell chemical biology
2. In Silico Modeling and Scoring of PROTAC-Mediated Ternary Complex Poses
   Liao, Junzhuo, Nie, Xueqing, Unarta, Ilona Christy, Ericksen, Spencer S., Tang, Weiping · 2022 · Journal of Medicinal Chemistry
3. Unveiling the hidden interactome of CRBN molecular glues
   Kheewoong Baek, Rebecca J. Metivier, Shourya S. Roy Burman, Jonathan W. Bushman, Hojong Yoon, Ryan J. Lumpkin, Julia K. Ryan, Dinah M. Abeja, Megha Lakshminarayan, Hong Yue et al. · 2025 · Nature Communications
4. The IMiD target CRBN determines HSP90 activity toward transmembrane proteins essential in multiple myeloma
   Michael Heider, Ruth Eichner, Jacob Stroh, Volker Morath, Anna Kuisl, Jana Zecha, Jannis Lawatscheck, Kheewoong Baek, Anne-Kathrin Garz, Martina Rudelius et al. · 2021 · Molecular Cell
5. Chemoproteomic-enabled phenotypic screening
   Louis Patrick Conway, Weichao Li, Christopher G. Parker · 2021 · Cell chemical biology
6. Opportunities and Challenges of Small Molecule Induced Targeted Protein Degradation
   Ming He, Wenxing Lv, Yu Rao · 2021 · Frontiers in Cell and Developmental Biology
7. E3 ligase ligand optimization of Clinical PROTACs
   Hanrui Jiang, Huan Xiong, Shuang-Xi Gu, Mingliang Wang · 2023 · Frontiers in Chemistry
8. Discovery of a Drug-like, Natural Product-Inspired DCAF11 Ligand Chemotype
   Gang Xue, Jianing Xie, Matthias Hinterndorfer, Marko Cigler, Lara Dötsch, Hana Imrichová, Philipp Lampe, Xiu‐Fen Cheng, Soheila Rezaei Adariani, Georg E. Winter et al. · 2023 · Nature Communications
9. Proteasome interaction with ubiquitinated substrates: from mechanisms to therapies
   Xiang Chen, Zaw Min Htet, Erika M. López-Alfonzo, Andreas Martin, Kylie J. Walters · 2020 · FEBS Journal
10. BRD4 (Bromodomain-Containing Protein 4) Interacts with GATA4 (GATA Binding Protein 4) to Govern Mitochondrial Homeostasis in Adult Cardiomyocytes
    Padmanabhan, Arun, Alexanian, Michael, Linares-Saldana, Ricardo, González-Terán, Bárbara, Andreoletti, Gaia, Huang, Yu, Connolly, Andrew J., Kim, Wonho, Hsu, Austin, Duan, Qiming et al. · 2020 · Circulation
11. Hydrophobic tagging-mediated degradation of Alzheimer's disease related Tau
    Gao, Na, Chu, Ting-Ting, Li, Qian-Qian, Lim, Yeh-Jun, Qiu, Tian, Ma, Meng-Rong, Hu, Zhi-Wen, Yang, Xi-Fei, Chen, Yong-Xiang, Zhao, Yu-Fen et al. · 2017 · RSC Advances
12. BET bromodomains as novel epigenetic targets for brain health and disease
    Mandakini B. Singh, Gregory C. Sartor · 2020 · Neuropharmacology
13. Fast-acting chemical tools to delineate causality in transcriptional control
    Martin G. Jaeger, Georg E. Winter · 2021 · Molecular Cell
14. Aminopyrazole based CDK9 PROTAC sensitizes pancreatic cancer cells to venetoclax
    Hannah M. King, Sandeep Rana, Sydney P. Kubica, Jayapal Reddy Mallareddy, Smitha Kizhake, Edward L. Ezell, Muhammad Zahid, Michael J. Naldrett, Sophie Alvarez, Henry C.-H. Law et al. · 2021 · Bioorganic & Medicinal Chemistry Letters
15. Development of a PROTAC-Based Targeting Strategy Provides a Mechanistically Unique Mode of Anti-Cytomegalovirus Activity
    Friedrich Hahn, Stuart T. Hamilton, Christina Wangen, Markus R. Wild, Jintawee Kicuntod, Nadine Brückner, Jasmine E. L. Follett, Lars Herrmann, Ahmed Kheimar, Benedikt B. Kaufer et al. · 2021 · International Journal of Molecular Sciences
16. Differences between lung adenocarcinoma and lung squamous cell carcinoma: Driver genes, therapeutic targets, and clinical efficacy
    Yue Liang Shen, Jie-Qi Chen, Xiangping Li · 2024 · Genes & Diseases
17. Resistance mechanisms and therapeutic strategies of CDK4 and CDK6 kinase targeting in cancer
    James John Asciolla, Xuewei Wu, Christos Adamopoulos, Evripidis Gavathiotis, Poulikos I. Poulikakos · 2025 · Nature Cancer
18. Targeting bromodomain and extraterminal proteins in breast cancer
    Jennifer M. Sahni, Ruth A. Keri · 2017 · Pharmacological Research
19. Mechanistic basis and efficacy of targeting the β-catenin–TCF7L2–JMJD6–c-Myc axis to overcome resistance to BET inhibitors
    Dyana T. Saenz, Warren C. Fiskus, Christopher Peter Mill, Dimuthu Nuwan Perera, Taghi Manshouri, Bernardo H Lara, Vrajesh A. Karkhanis, Sunil Sharma, Stephen K. Horrigan, Prithviraj Bose et al. · 2020 · Blood
20. Proteolysis targeting chimeras (PROTACs) for epigenetics research
    Anja Vogelmann, Dina Robaa, Wolfgang Sippl, Manfred Jung · 2020 · Current Opinion in Chemical Biology
21. Rapid synthesis of pomalidomide-conjugates for the development of protein degrader libraries
    Duncan K. Brownsey, Ben C. Rowley, Evgueni Gorobets, Benjamin S. Gelfand, Darren J. Derksen · 2021 · Chemical Science
22. Selectivity On-Target of Bromodomain Chemical Probes by Structure-Guided Medicinal Chemistry and Chemical Biology
    Carles Galdeano, Alessio Ciulli · 2016 · Future Medicinal Chemistry
23. PAX3-FOXO1: Zooming in on an “undruggable” target
    Marco Wachtel, Beat W. Schäfer · 2017 · Seminars in Cancer Biology
24. New Class of Selective Estrogen Receptor Degraders (SERDs): Expanding the Toolbox of PROTAC Degrons
    Lucia Wang, Valeria Sanabria Guillen, Naina Sharma, Kevin Flessa, Jian Min, Kathryn E. Carlson, Weiyi Toy, Sara Braqi, Benita S. Katzenellenbogen, John A. Katzenellenbogen et al. · 2018 · ACS Medicinal Chemistry Letters
25. Discovery of a PROTAC targeting ALK with in vivo activity
    Guoyi Yan, Xin-Xin Zhong, Yue Lin, Chunlan Pu, Huifang Shan, Suke Lan, Meng Zhou, Xueyan Hou, Jie Yang, Rui Li · 2021 · European Journal of Medicinal Chemistry
26. An important role for Myb-MuvB and its target gene KIF23 in a mouse model of lung adenocarcinoma
    Fabian Iltzsche, Katalenić Simon, Sabine Stopp, Grit Pattschull, S Francke, P Wolter, Stefanie Hauser, Daniel J. Murphy, Paloma García, Andreas Rosenwald et al. · 2016 · Oncogene
27. Functional Roles of Bromodomain Proteins in Cancer
    Samuel P. Boyson, Cong Gao, Kathleen May Quinn, Joseph R. Boyd, Hana Paculová, Seth E. Frietze, Karen C. Glass · 2021 · Cancers
28. Selective degradation of histone deacetylase 8 mediated by a proteolysis targeting chimera (PROTAC)
    Jiranan Chotitumnavee, Yasunobu Yamashita, Yukari Takahashi, Yuri Takada, Tetsuya Iida, Makoto Oba, Yukihiro Itoh, Takayoshi Suzuki · 2022 · Chemical Communications
29. Covalent drugs targeting histidine – an unexploited opportunity?
    Jianwei Che, Lyn H. Jones · 2022 · RSC Medicinal Chemistry
30. G4-PROTAC: targeted degradation of a G-quadruplex binding protein
    Kiran M. Patil, Danielle Chin, Hui Ling Seah, Qi Shi, Kah Wai Lim, Anh Tuân Phan · 2021 · Chemical Communications
31. Optimization of PROTAC Ternary Complex Using DNA Encoded Library Approach
    Qiuxia Chen, Chuan Liu, Wei Wang, Xiaoyun Meng, Xue‐Min Cheng, Xian-Yang Li, Longying Cai, Linfu Luo, Xu He, Huan Qu et al. · 2023 · ACS Chemical Biology
32. Current advances of small molecule E3 ligands for proteolysis-targeting chimeras design
    Dazhao Mi, Yuzhan Li, Haijun Gu, Yan Li, Yihua Chen · 2023 · European Journal of Medicinal Chemistry
33. Nanoreceptors promote mutant p53 protein degradation by mimicking selective autophagy receptors
    Xiaowan Huang, Ziyang Cao, Jieying Qian, Tao Ding, Yanxia Wu, Hao Zhang, Suqin Zhong, Xiaoli Wang, Xiaoguang Ren, Wang Zhang et al. · 2024 · Nature Nanotechnology
34. Therapies for the Treatment of Advanced/Metastatic Estrogen Receptor-Positive Breast Cancer: Current Situation and Future Directions
    Rohan Kalyan Rej, Joyeeta Roy, Srinivasa Rao Allu · 2024 · Cancers
35. Bromodomain and extraterminal proteins foster the core transcriptional regulatory programs and confer vulnerability in liposarcoma
    Ye Chen, Liang Xu, Anand Mayakonda, Mo-Li Huang, Deepika Kanojia, Tuan Zea Tan, Pushkar Dakle, Ruby Yu‐Tong Lin, Xinyu Ke, JONATHAN W. SAID et al. · 2019 · Nature Communications
36. Epigenetic therapies in acute myeloid leukemia: where to from here?
    Katie A. Fennell, Charles C. Bell, Mark A. Dawson · 2019 · Blood
37. Clues to molecular glues
    Thomas M. Geiger, Sabine C. Schäfer, Johannes Kilian Dreizler, Michael Walz, Felix Hausch · 2021 · Current Research in Chemical Biology
38. Opportunities for Therapeutic Modulation of O-GlcNAc
    Steven S. Cheng, Alison C. Mody, Christina M. Woo · 2024 · Chemical Reviews
39. Design and Characterization of Novel Covalent Bromodomain and Extra-Terminal Domain (BET) Inhibitors Targeting a Methionine
    Olesya A. Kharenko, Reena G. Patel, S. David Brown, Cyrus Calosing, André White, Lakshminarasimhan Damodharan, R.K. Suto, Bryan C. Duffy, Douglas B. Kitchen, Kevin G. McLure et al. · 2018 · Journal of Medicinal Chemistry
40. Using Chemical Epigenetics to Target Cancer
    Virangika K. Wimalasena, Tingjian Wang, Logan H. Sigua, Adam David Durbin, Jun Qi · 2020 · Molecular Cell
41. RING domains act as both substrate and enzyme in a catalytic arrangement to drive self-anchored ubiquitination
    L. Kiss, Dean Clift, Nadine Renner, David Neuhaus, Leo C. James · 2021 · Nature Communications
42. Enriching Proteolysis Targeting Chimeras with a Second Modality: When Two Are Better Than One
    Alessandra Salerno, Francesca Seghetti, Jessica Caciolla, Elisa Uliassi, Eleonora Testi, Melissa Guardigni, Marinella Roberti, Andrea Milelli, María Laura Bolognesi · 2022 · Journal of Medicinal Chemistry
43. Targeted Protein O-GlcNAcylation Using Bifunctional Small Molecules
    Bowen Ma, Khadija Shahed Khan, Tongyang Xu, Josefina Xeque Amada, Zhihao Guo, Yunpeng Huang, Yu Yan, Henry Lam, Alfred S.L. Cheng, Wai‐Lung Ng · 2024 · Journal of the American Chemical Society
44. Degradation of huntingtin mediated by a hybrid molecule composed of IAP antagonist linked to phenyldiazenyl benzothiazole derivative
    Shusuke Tomoshige, Sayaka Nomura, Kenji Ohgane, Yuichi Hashimoto, Minoru Ishikawa · 2018 · Bioorganic & Medicinal Chemistry Letters
45. Ligand-mediated protein degradation reveals functional conservation among sequence variants of the CUL4-type E3 ligase substrate receptor cereblon
    Afua Adutwumwa Akuffo, Aileen Y. Alontaga, Rainer S. Metcalf, Matthew S. Beatty, Andreas Becker, Jessica M. McDaniel, Rebecca S. Hesterberg, William E. Goodheart, Steven Gunawan, Muhammad Ayaz et al. · 2018 · Journal of Biological Chemistry
46. Efficient Synthesis of Immunomodulatory Drug Analogues Enables Exploration of Structure–Degradation Relationships
    George M. Burslem, Philipp Ottis, Saul Jaime‐Figueroa, Alicia R. Morgan, Philipp M. Cromm, Momar Toure, Craig M. Crews · 2018 · ChemMedChem
47. Different Degradation Mechanisms of Inhibitor of Apoptosis Proteins (IAPs) by the Specific and Nongenetic IAP-Dependent Protein Eraser (SNIPER)
    Nobumichi Ohoka, Osamu Ujikawa, Kenichiro Shimokawa, Tomoya Sameshima, Norihito Shibata, Takayuki Hattori, Hiroshi Nara, Nobuo Cho, Mikihiko Naito · 2018 · Chemical and Pharmaceutical Bulletin
48. Small molecule PROTACs in targeted therapy: An emerging strategy to induce protein degradation
    Meiyang Xi, Yi Chen, Hongyu Yang, Huiting Xu, Kui Du, Chunlei Wu, Yanfei Xu, Liping Deng, Xiang Luo, Lemao Yu et al. · 2019 · European Journal of Medicinal Chemistry
49. TDP-43 specific reduction induced by Di-hydrophobic tags conjugated peptides
    Na Gao, Yunpeng Huang, Tingting Chu, Qianqian Li, Bing Nan Zhou, Yong‐Xiang Chen, Yufen Zhao, Yanmei Li · 2018 · Bioorganic Chemistry
50. Targeted Protein Degradation by Chimeric Small Molecules, PROTACs and SNIPERs
    Mikihiko Naito, Nobumichi Ohoka, Norihito Shibata, Yoshinori Tsukumo · 2019 · Frontiers in Chemistry
51. Leveraging Ligand Affinity and Properties: Discovery of Novel Benzamide-Type Cereblon Binders for the Design of PROTACs
    Christian Steinebach, Aleša Bricelj, Arunima Murgai, Izidor Sosič, Luca Bischof, Yuen Lam Dora Ng, Christopher Heim, Samuel A. Maiwald, Matic Proj, Rabea Voget et al. · 2023 · Journal of Medicinal Chemistry
52. Bifunctional Small Molecules That Induce Nuclear Localization and Targeted Transcriptional Regulation
    William J. Gibson, Ananthan Sadagopan, Veronika M. Shoba, Amit Choudhary, Matthew M. Meyerson, Stuart L. Schreiber · 2023 · Journal of the American Chemical Society
53. Dual-Action-Only PROTACs
    Ranit Dutta, Anirudh Devarajan, Amelia Talluri, Ritam Das, S. Thayumanavan · 2025 · Journal of the American Chemical Society
54. Protein-slaying drugs could be the next blockbuster therapies
    Megan Scudellari · 2019 · Nature
55. A critical evaluation of the approaches to targeted protein degradation for drug discovery
    Chopra, Rajesh, Sadok, Amine, Collins, Ian · 2019 · Drug Discovery Today: Technologies
56. Role of BET Proteins in Inflammation and CNS Diseases
    Lei Liu, Changjun Yang, Eduardo Candelario‐Jalil · 2021 · Frontiers in Molecular Biosciences
57. Identification of a selective BRD4 PROTAC with potent antiproliferative effects in AR-positive prostate cancer based on a dual BET/PLK1 inhibitor
    Rong Hu, Wanli Wang, Ying-Yue Yang, Xia-Tong Hu, Qiwei Wang, Weiqiong Zuo, Ying Xu, Qiang Feng, Ningyu Wang · 2021 · European Journal of Medicinal Chemistry
58. Profiling of diverse tumor types establishes the broad utility of VHL-based ProTaCs and triages candidate ubiquitin ligases
    Xin Luo, Ivonne Archibeque, Ken Dellamaggiore, Kate Smither, Oliver R. Homann, James Russell Lipford, Dane A. Mohl · 2022 · iScience
59. BRD4: a general regulator of transcription elongation
    Elisabeth Altendorfer, Yelizaveta Mochalova, Andreas Mayer · 2022 · Transcription
60. Chemical Knockdown of Phosphorylated p38 Mitogen-Activated Protein Kinase (MAPK) as a Novel Approach for the Treatment of Alzheimer′s Disease
    Seung Hwan Son, Na‐Rae Lee, Min Sung Gee, Chae Won Song, Soojin Lee, Sang‐Kyung Lee, Yoonji Lee, Hee Jin Kim, Jong Kil Lee, Kyung‐Soo Inn et al. · 2023 · ACS Central Science
61. Selective BET bromodomain inhibition as an antifungal therapeutic strategy
    Flore Mietton, Elena Ferri, Morgane Champleboux, Ninon Zala, Danièle Maubon, Yingsheng Zhou, M. Harbut, Didier Spittler, Cécile Garnaud, Marie Courçon et al. · 2017 · Nature Communications
62. Unmasking Amides: Ruthenium-Catalyzed Protodecarbonylation of N-Substituted Phthalimide Derivatives
    Yu‐Chao Yuan, Raghu Kamaraj, Christian Bruneau, Thierry Labasque, Thierry Roisnel, Rafael Gramage‐Doria · 2017 · Organic Letters
63. Design, Synthesis, and Evaluation of Potent, Selective, and Bioavailable AKT Kinase Degraders
    Xufen Yu, Jia Xu, Ling Xie, Li Wang, Yudao Shen, Kaitlyn M. Cahuzac, Xian Chen, Jing Liu, Ramon E. Parsons, Jian Jun Jin · 2021 · Journal of Medicinal Chemistry
64. Efficient protein knockdown of HaloTag-fused proteins using hybrid molecules consisting of IAP antagonist and HaloTag ligand
    Shusuke Tomoshige, Yuichi Hashimoto, Minoru Ishikawa · 2016 · Bioorganic & Medicinal Chemistry
65. Pharmacological difference between degrader and inhibitor against oncogenic BCR-ABL kinase
    Norihito Shibata, Kenichiro Shimokawa, Katsunori Nagai, Nobumichi Ohoka, Takayuki Hattori, Naoki Miyamoto, Osamu Ujikawa, Tomoya Sameshima, Hiroshi Nara, Nobuo Cho et al. · 2018 · Scientific Reports
66. Ushering in the next generation of precision trials for pediatric cancer
    Steven G. DuBois, Laura Corson, Kimberly Stegmaier, Katherine A. Janeway · 2019 · Science
67. Protein targeting chimeric molecules specific for dual bromodomain 4 (BRD4) and Polo-like kinase 1 (PLK1) proteins in acute myeloid leukemia cells
    Xupeng Mu, Liting Bai, Yaya Xu, Jingyao Wang, Haibin Lu · 2019 · Biochemical and Biophysical Research Communications
68. Chemically induced degradation of CK2 by proteolysis targeting chimeras based on a ubiquitin-proteasome pathway
    Chen, Hong, Chen, Feihong, Liu, Nannan, Wang, Xinyi, Gou, Shaohua · 2018 · Bioorganic Chemistry
69. Targeted Degradation of Transcription Coactivator SRC‐1 through the N‐Degron Pathway
    Yeongju Lee, Jiwon Heo, Hoibin Jeong, Kyung Tae Hong, Do Hoon Kwon, Min Hyeon Shin, Misook Oh, Ganesh A. Sable, G‐One Ahn, Jun‐Seok Lee et al. · 2020 · Angewandte Chemie International Edition
70. Chromatin Looping Shapes KLF5-dependent Transcriptional Programs in Human Epithelial Cancers
    Yan-Li Liu, Bingqian Guo, Estrella Aguilera-Jimenez, Vivian Chu, Jin Zhou, Zhong Wu, J. Francis, Xiao-Jun Yang, P. Choi, Swneke D. Bailey et al. · 2020 · Cancer Research
71. MDM2-Based Proteolysis-Targeting Chimeras (PROTACs): An Innovative Drug Strategy for Cancer Treatment
    André T. S. Vicente, Jorge A. R. Salvador · 2022 · International Journal of Molecular Sciences
72. Machine Learning Modeling of Protein-Intrinsic Features Predicts Tractability of Targeted Protein Degradation
    Zhang, Wubing, Roy Burman, Shourya S., Chen, Jiaye, Donovan, Katherine A., Cao, Yang, Shu, Chelsea, Zhang, Boning, Zeng, Zexian, Gu, Shengqing, Zhang, Yi et al. · 2022 · Genomics, Proteomics & Bioinformatics
73. Clinical Translation of Targeted Protein Degraders
    Nikki R. Kong, Lyn H. Jones · 2023 · Clinical Pharmacology & Therapeutics
74. The molecular mechanism of thalidomide analogs in hematologic malignancies
    Stefanie Lindner, Jan Krönke · 2016 · Journal of Molecular Medicine
75. Kinase-independent function of E-type cyclins in liver cancer
    Yan Geng, Wojciech Michowski, Joel M. Chick, Yaoyu E. Wang, Marie Jecrois, Katharine E. Sweeney, Lijun Liu, Richard C. Han, Nan Ke, Agnieszka Zagożdżon et al. · 2018 · Proceedings of the National Academy of Sciences
76. The Role of AP-1 Transcription Factors in Plasma Cell Biology and Multiple Myeloma Pathophysiology
    Fengjuan Fan, Klaus Podar · 2021 · Cancers
77. A modular PROTAC design for target destruction using a degradation signal based on a single amino acid
    Karthigayan Shanmugasundaram, Peng Shao, Han Chen, Bismarck Campos, Stanton F. McHardy, Tuoping Luo, Hai Rao · 2019 · Journal of Biological Chemistry
78. Targeted Protein Degradation for Infectious Diseases: from Basic Biology to Drug Discovery
    Rocío Marisol Espinoza-Chávez, Alessandra Salerno, Anastasia Liuzzi, Andrea Ilari, Andrea Milelli, Elisa Uliassi, María Laura Bolognesi · 2022 · ACS Bio & Med Chem Au
79. Catalytic Degraders Effectively Address Kinase Site Mutations in EML4-ALK Oncogenic Fusions
    Yang Gao, Baishan Jiang, Hellen Kim, Matthew J. Berberich, Jianwei Che, Katherine A. Donovan, John M. Hatcher, Fidel Huerta, Nicholas P. Kwiatkowski, Yingpeng Liu et al. · 2023 · Journal of Medicinal Chemistry
80. A CRISPR activation screen identifies FBXO22 supporting targeted protein degradation
    Ananya A. Basu, Chenlu Zhang, Isabella A. Riha, Assa Magassa, Miguel A. Lorenzo Campos, Alana G. Caldwell, Felicia Ko, Xiaoyu Zhang · 2024 · Nature Chemical Biology
81. Drugging Chromatin in Cancer: Recent Advances and Novel Approaches
    Sheng F. Cai, Chun-Wei David Chen, Scott A. Armstrong · 2015 · Molecular Cell
82. H3K36 Methyltransferases as Cancer Drug Targets: Rationale and Perspectives for Inhibitor Development
    David S. Rogawski, Jolanta E. Grembecka, Tomasz Cierpicki · 2016 · Future Medicinal Chemistry
83. Targeted Degradation of Proteins Localized in Subcellular Compartments by Hybrid Small Molecules
    Keiichiro Okuhira, Takuji Shoda, Risa Omura, Nobumichi Ohoka, Takayuki Hattori, Norihito Shibata, Yosuke Demizu, Ryo Sugihara, Asato Ichino, Haruka Kawahara et al. · 2016 · Molecular Pharmacology
84. Triazol: A Privileged Scaffold for Proteolysis Targeting Chimeras
    Liwen Xia, Meng-Yu Ba, Wei Liu, Weyland Cheng, Chao-Ping Hu, Qing Zhao, Yongfang Yao, Moran Sun, Yongtao Duan · 2019 · Future Medicinal Chemistry
85. PROTAC technology for the treatment of Alzheimer’s disease: advances and perspectives
    Hiroyuki Inuzuka, Jing Liu, Wenyi Wei, Abdol-Hossein Rezaeian · 2022 · Acta Materia Medica
86. Discovery and Structural Characterization of Small Molecule Binders of the Human CTLH E3 Ligase Subunit GID4
    Chetan K. Chana, Pierre Maisonneuve, Ganna Posternak, Nicolas G.A. Grinberg, Juline Poirson, Samara Mishelle Ona, Derek F. J. Ceccarelli, P. Mäder, Daniel J. St‐Cyr, Victor P.T. Pau et al. · 2022 · Journal of Medicinal Chemistry
87. Acute perturbation strategies in interrogating RNA polymerase II elongation factor function in gene expression
    Bin Zheng, Yuki Aoi, Avani P. Shah, Marta Iwanaszko, Siddhartha Das, Emily Jane Rendleman, Didi Zha, Nabiha Haleema Khan, Edwin R. Smith, Ali Shilatifard · 2021 · Genes & Development
88. Proteasome-Independent Protein Knockdown by Small-Molecule Inhibitor for the Undruggable Lung Adenocarcinoma
    Wei Zhou, Guogui Sun, Zhen Zhang, Libo Zhao, Li Xu, Hongyu Yuan, Shumu Li, Zaizai Dong, Yongmei Song, Xiaohong Fang · 2019 · Journal of the American Chemical Society
89. Discovery of a new class of PROTAC BRD4 degraders based on a dihydroquinazolinone derivative and lenalidomide/pomalidomide
    Fangqing Zhang, Zhenwei Wu, Pan Chen, Jian Zhang, Tao Wang, Jinpei Zhou, Huibin Zhang · 2019 · Bioorganic & Medicinal Chemistry
90. Discovery of novel small molecule induced selective degradation of the bromodomain and extra-terminal (BET) bromodomain protein BRD4 and BRD2 with cellular potencies
    Jiang, Fei, Wei, Qingyun, Li, Huili, Li, Hongmei, Cui, Yong, Ma, Yu, Chen, Haifang, Cao, Peng, Lu, Tao, Chen, Yadong · 2020 · Bioorganic & Medicinal Chemistry
91. PROTAC Bromodomain Inhibitor ARV-825 Displays Anti-Tumor Activity in Neuroblastoma by Repressing Expression of MYCN or c-Myc
    Zhiheng Li, Su Lin Lim, Yanfang Tao, Xiaolu Li, Yi Xie, Chun Yang, Zimu Zhang, You Jiang, Xianbing Zhang, Xu Cao et al. · 2020 · Frontiers in Oncology
92. The Role of the Ubiquitin Proteasome System in Glioma: Analysis Emphasizing the Main Molecular Players and Therapeutic Strategies Identified in Glioblastoma Multiforme
    Semer Maksoud · 2021 · Molecular Neurobiology
93. Site-Specific Chemoenzymatic Conjugation of High-Affinity M6P Glycan Ligands to Antibodies for Targeted Protein Degradation
    Xiao Zhang, Huiying Liu, Jia He, Chong Ou, Thomas Connor Donahue, Musleh M. Muthana, Lishan Su, Lai‐Xi Wang · 2022 · ACS Chemical Biology
94. Discovery of a potent and selective proteolysis targeting chimera (PROTAC) degrader of NSD3 histone methyltransferase
    Yaoliang Sun, Ying Zhang, Xiaoai Chen, Aisong Yu, Wenhao Du, Yuting Huang, Feifei Wu, Lei Yu, Jiayi Li, Cuiyun Wen et al. · 2022 · European Journal of Medicinal Chemistry
95. A Cell-Permeant Nanobody-Based Degrader That Induces Fetal Hemoglobin
    Fangfang Shen, Ge Zheng, Mekedlawit T. Setegne, Karin Tenglin, Manizheh Izadi, Henry T.H. Xie, Liting Zhai, Stuart H. Orkin, Laura M. K. Dassama · 2022 · ACS Central Science
96. BRD4: New hope in the battle against glioblastoma
    Weichen Duan, Miao Yu, Jiajia Chen · 2023 · Pharmacological Research
97. Open Access Chemical Probes for Epigenetic Targets
    Peter J. Brown, Susanne Müller · 2015 · Future Medicinal Chemistry
98. Next-Generation Drugs and Probes for Chromatin Biology: From Targeted Protein Degradation to Phase Separation
    Kateřina Čermáková, H. Courtney Hodges · 2018 · Molecules
99. Dynamic Imaging of Small Molecule Induced Protein–Protein Interactions in Living Cells with a Fluorophore Phase Transition Based Approach
    Chan-I Chung, Qiang Zhang, Xiaokun Shu · 2018 · Analytical Chemistry
100. Exploring Degradation of Mutant and Wild-Type Epidermal Growth Factor Receptors Induced by Proteolysis-Targeting Chimeras
     Xufen Yu, Meng Cheng, Kaylene J. Lu, Yudao Shen, Yue Zhong, Jing Liu, Yue Xiong, Jian Jun Jin · 2022 · Journal of Medicinal Chemistry